Lynx1 Capital Management LP
10% ownerLynx1 Capital Management LP (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Passage Bio, Inc. (PASG). Across 1 priced purchase filing, the average 21-session return was +1.5% from execution and -0.7% from disclosure (delay-adjusted; derived). The largest single filing was $854K of KRRO (77,299 sh across 3 lots, as filed), executed Oct 22. Data as of Nov 8 2026.
Add to watchlistMedian ADV $2.6M across their filed names
50% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Shares × price, as filed · by filing month · past 24 months
Sector per market data · by filing · past 12 months
77,299 sh across 3 lots
Exec Oct 22
Filed Oct 26 · 6:37 PM ET PASGPURCHASE Passage Bio, Inc. View filing → $206K
50,055 sh × $4.12
Exec Jun 25
Filed Jun 29 · 4:30 PM ET CGEMPURCHASE Cullinan Therapeutics, Inc. View filing → $1.4M
165,667 sh × $8.40
Exec Oct 28 2025
Filed Oct 30 2025 · 5:13 PM ET NEUPPURCHASE Neuphoria Therapeutics Inc. View filing → $3.3M
639,110 sh × $5.14
Exec Oct 21 2025
Filed Oct 23 2025 · 7:49 PM ET CGEMPURCHASE Cullinan Therapeutics, Inc. View filing → $2.1M
248,749 sh across 4 lots
Exec Oct 14 2025
Filed Oct 21 2025 · 7:00 PM ET † CGEMPURCHASE Cullinan Therapeutics, Inc. View filing → $9.8M
1,459,641 sh across 3 lots
Exec Oct 8 2025
Filed Oct 10 2025 · 6:58 PM ET PASGPURCHASE Passage Bio, Inc. View filing → $138K
19,783 sh × $6.99
Exec Sep 12 2025
Filed Sep 15 2025 · 8:05 PM ET PASGPURCHASE Passage Bio, Inc. View filing → $662K
115,725 sh across 2 lots
Exec Jul 23 2025
Filed Jul 24 2025 · 6:12 PM ET More filings →